"description","label","id","name","rationale","instanceType","uuid:ID"
"The main design for the study","","StudyDesign_1","Study Design 1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyDesign","c24f7f65-1523-42a7-acec-8256baaeecb7"
